0 10 Engagement engagement NN 11 13 of of IN 14 17 the the DT 18 23 Lewis Lewis NNP 24 25 X X NNP 26 33 antigen antigen NN 34 35 ( ( ( 35 39 CD15 cd15 NN 39 40 ) ) ) 41 48 results result VBZ 49 51 in in IN 52 60 monocyte monocyte NN 61 71 activation activation NN 71 72 . . . 74 76 We we PRP 77 87 previously previously RB 88 96 reported report VBD 97 101 that that IN 102 110 monocyte monocyte NN 111 119 adhesion adhesion NN 120 122 to to TO 123 128 tumor tumor NN 129 137 necrosis necrosis NN 138 150 factor-alpha factor-alpha NN 151 152 ( ( ( 152 170 TNF-alpha)-treated tnf-alpha)-treated JJ 171 182 endothelial endothelial JJ 183 188 cells cell NNS 189 198 increased increase VBD 199 209 expression expression NN 210 212 of of IN 213 219 tissue tissue NN 220 226 factor factor NN 227 230 and and CC 231 235 CD36 cd36 NN 236 238 on on IN 239 248 monocytes monocyte NNS 248 249 . . . 250 255 Using use VBG 256 269 immunological immunological JJ 270 283 cross-linking cross-linking NN 284 286 to to TO 287 292 mimic mimic VB 293 301 receptor receptor NN 302 312 engagement engagement NN 313 315 by by IN 316 323 natural natural JJ 324 331 ligands ligand NNS 331 332 , , , 333 335 we we PRP 336 339 now now RB 340 344 show show VBP 345 349 that that IN 350 354 CD15 CD15 NNP 355 356 ( ( ( 356 361 Lewis Lewis NNP 362 363 X X NNP 363 364 ) ) ) 364 365 , , , 366 367 a a DT 368 376 monocyte monocyte NN 377 393 counter-receptor counter-receptor NN 394 397 for for IN 398 409 endothelial endothelial JJ 410 419 selectins selectin NNS 420 423 may may MD 424 435 participate participate VB 436 438 in in IN 439 443 this this DT 444 452 response response NN 452 453 . . . 454 456 We we PRP 457 461 used use VBD 462 470 cytokine cytokine NN 471 481 production production NN 482 484 as as IN 485 486 a a DT 487 494 readout readout NN 495 498 for for IN 499 507 monocyte monocyte NN 508 518 activation activation NN 519 522 and and CC 523 528 found find VBD 529 533 that that IN 534 538 CD15 cd15 NN 539 552 cross-linking cross-linking NN 553 560 induced induce VBD 561 570 TNF-alpha TNF-alpha NNP 571 578 release release NN 579 583 from from IN 584 594 peripheral peripheral JJ 595 600 blood blood NN 601 610 monocytes monocyte NNS 611 614 and and CC 615 620 cells cell NNS 621 625 from from IN 626 629 the the DT 630 639 monocytic monocytic JJ 640 644 cell cell NN 645 649 line line NN 650 653 MM6 mm6 NN 653 654 . . . 655 667 Quantitative quantitative JJ 668 675 reverse reverse JJ 676 700 transcriptase-polymerase transcriptase-polymerase NN 701 706 chain chain NN 707 715 reaction reaction NN 716 717 ( ( ( 717 723 RT-PCR RT-PCR NNP 723 724 ) ) ) 725 731 showed show VBD 732 734 an an DT 735 743 increase increase NN 744 746 in in IN 747 759 steady-state steady-state JJ 760 769 TNF-alpha TNF-alpha NNP 770 774 mRNA mRNA NNP 775 780 after after IN 781 782 3 3 CD 783 785 to to TO 786 787 4 4 CD 788 793 hours hour NNS 794 796 of of IN 797 810 cross-linking cross-linking NN 810 811 . . . 812 816 CD15 CD15 NNP 817 830 cross-linking cross-linking NN 831 835 also also RB 836 849 concomitantly concomitantly RB 850 859 increased increase VBD 860 873 interleukin-1 interleukin-1 NN 874 878 beta beta NN 879 880 ( ( ( 880 884 IL-1 il-1 NN 885 889 beta beta NN 889 890 ) ) ) 891 895 mRNA mRNA NNP 895 896 , , , 897 902 while while IN 903 905 no no DT 906 914 apparent apparent JJ 915 921 change change NN 922 925 was be VBD 926 934 observed observe VBN 935 937 in in IN 938 941 the the DT 942 948 levels level NNS 949 951 of of IN 952 962 beta-actin beta-actin NN 963 967 mRNA mRNA NNP 967 968 , , , 969 979 indicating indicate VBG 980 991 specificity specificity NN 991 992 . . . 993 995 To to TO 996 1003 examine examine VB 1004 1019 transcriptional transcriptional JJ 1020 1030 regulation regulation NN 1031 1033 of of IN 1034 1042 cytokine cytokine NN 1043 1048 genes gene NNS 1049 1051 by by IN 1052 1056 CD15 cd15 NN 1057 1067 engagement engagement NN 1067 1068 , , , 1069 1070 a a DT 1071 1074 CAT CAT NNP 1075 1082 plasmid plasmid NN 1083 1091 reporter reporter NN 1092 1101 construct construct NN 1102 1112 containing contain VBG 1113 1117 IL-1 il-1 NN 1118 1122 beta beta NN 1123 1140 promoter/enhancer promoter/enhancer NN 1141 1150 sequences sequence NNS 1151 1154 was be VBD 1155 1165 introduced introduce VBN 1166 1170 into into IN 1171 1174 MM6 MM6 NNP 1174 1175 . . . 1176 1186 Subsequent subsequent JJ 1187 1200 cross-linking cross-linking NN 1201 1203 of of IN 1204 1208 CD15 CD15 NNP 1209 1218 increased increase VBD 1219 1222 CAT CAT NNP 1223 1231 activity activity NN 1231 1232 . . . 1233 1237 CD15 CD15 NNP 1238 1248 engagement engagement NN 1249 1251 by by IN 1252 1262 monoclonal monoclonal JJ 1263 1271 antibody antibody NN 1272 1276 also also RB 1277 1287 attenuated attenuate VBD 1288 1292 IL-1 il-1 NN 1293 1297 beta beta NN 1298 1308 transcript transcript NN 1309 1320 degradation degradation NN 1320 1321 , , , 1322 1335 demonstrating demonstrate VBG 1336 1340 that that IN 1341 1350 signaling signaling NN 1351 1354 via via IN 1355 1359 CD15 CD15 NNP 1360 1364 also also RB 1365 1368 had have VBD 1369 1388 posttranscriptional posttranscriptional JJ 1389 1396 effects effect NNS 1396 1397 . . . 1398 1405 Nuclear nuclear JJ 1406 1414 extracts extract NNS 1415 1417 of of IN 1418 1427 anti-CD15 anti-cd15 JJ 1428 1440 cross-linked cross-linked JJ 1441 1446 cells cell NNS 1447 1459 demonstrated demonstrate VBD 1460 1468 enhanced enhance VBN 1469 1475 levels level NNS 1476 1478 of of IN 1479 1482 the the DT 1483 1498 transcriptional transcriptional JJ 1499 1505 factor factor NN 1506 1515 activator activator NN 1516 1525 protein-1 protein-1 NN 1525 1526 , , , 1527 1536 minimally minimally RB 1537 1544 changed change VBD 1545 1552 nuclear nuclear JJ 1553 1565 factor-kappa factor-kappa NN 1566 1567 B B NNP 1567 1568 , , , 1569 1572 and and CC 1573 1576 did do VBD 1577 1580 not not RB 1581 1587 affect affect VB 1588 1592 SV40 sv40 NN 1593 1601 promoter promoter NN 1602 1610 specific specific JJ 1611 1620 protein-1 protein-1 NN 1620 1621 . . . 1622 1624 We we PRP 1625 1633 conclude conclude VBP 1634 1638 that that IN 1639 1649 engagement engagement NN 1650 1652 of of IN 1653 1657 CD15 cd15 NN 1658 1660 on on IN 1661 1670 monocytes monocyte NNS 1671 1678 results result VBZ 1679 1681 in in IN 1682 1690 monocyte monocyte NN 1691 1701 activation activation NN 1701 1702 . . . 1703 1705 In in IN 1706 1714 addition addition NN 1715 1717 to to TO 1718 1721 its its PRP$ 1722 1737 well-recognized well-recognized JJ 1738 1746 adhesive adhesive JJ 1747 1751 role role NN 1751 1752 , , , 1753 1757 CD15 CD15 NNP 1758 1761 may may MD 1762 1770 function function VB 1771 1773 as as IN 1774 1776 an an DT 1777 1786 important important JJ 1787 1796 signaling signal VBG 1797 1805 molecule molecule NN 1806 1813 capable capable JJ 1814 1816 of of IN 1817 1827 initiating initiate VBG 1828 1843 proinflammatory proinflammatory JJ 1844 1850 events event NNS 1851 1853 in in IN 1854 1863 monocytes monocyte NNS 1864 1868 that that WDT 1869 1873 come come VBP 1874 1878 into into IN 1879 1886 contact contact NN 1887 1891 with with IN 1892 1901 activated activate VBN 1902 1913 endothelium endothelium NN 1913 1914 . . .